ABSTRACT
AF in MS results in significant mortality and morbidity. Anticoagulation remains the mainstay for preventing thromboembolic complications. Rate control with AV nodal blocking agents is the current practice of choice, however rhythm control is emerging as an upcoming strategy in selected subgroup of patients.
